2.15
price up icon1.90%   0.04
pre-market  Vorhandelsmarkt:  2.10   -0.05   -2.33%
loading
Schlusskurs vom Vortag:
$2.11
Offen:
$2.12
24-Stunden-Volumen:
121.98K
Relative Volume:
0.63
Marktkapitalisierung:
$30.84M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-26.26M
KGV:
-0.3145
EPS:
-6.8353
Netto-Cashflow:
$-26.82M
1W Leistung:
+27.22%
1M Leistung:
+35.22%
6M Leistung:
-56.78%
1J Leistung:
-37.23%
1-Tages-Spanne:
Value
$2.06
$2.16
1-Wochen-Bereich:
Value
$1.64
$2.18
52-Wochen-Spanne:
Value
$1.20
$6.115

Tempest Therapeutics Inc Stock (TPST) Company Profile

Name
Firmenname
Tempest Therapeutics Inc
Name
Telefon
415-798-8589
Name
Adresse
2000 SIERRA POINT PARKWAY, BRISBANE
Name
Mitarbeiter
4
Name
Twitter
Name
Nächster Verdiensttermin
2026-05-12
Name
Neueste SEC-Einreichungen
Name
TPST's Discussions on Twitter

Compare TPST vs VRTX, REGN, ARGX, ALNY, ONC

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
TPST icon
TPST
Tempest Therapeutics Inc
2.15 30.84M 0 -26.26M -26.82M -6.8353
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
424.36 107.87B 12.32B 4.34B 3.19B 16.86
REGN icon
REGN
Regeneron Pharmaceuticals Inc
702.27 73.63B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
794.70 49.42B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
301.11 40.20B 3.71B 313.75M 465.38M 2.2571
ONC icon
ONC
Beone Medicines Ltd Adr
297.49 33.06B 5.36B 287.73M 924.18M 2.5229

Tempest Therapeutics Inc Stock (TPST) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2026-01-22 Hochstufung H.C. Wainwright Neutral → Buy
2025-04-10 Herabstufung H.C. Wainwright Buy → Neutral
2025-04-10 Herabstufung Scotiabank Sector Outperform → Sector Perform
2024-03-14 Eingeleitet Scotiabank Sector Outperform
2024-02-08 Eingeleitet Jefferies Buy

Tempest Therapeutics Inc Aktie (TPST) Neueste Nachrichten

pulisher
May 05, 2026

MSN Money - MSN

May 05, 2026
pulisher
Apr 30, 2026

TPST Q1'26 Earnings: revenue estimate is 0 USD - TradingView

Apr 30, 2026
pulisher
Apr 29, 2026

After six complete responses, Tempest brings updated CAR-T data to Dublin - Stock Titan

Apr 29, 2026
pulisher
Apr 29, 2026

Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting - Sahm

Apr 29, 2026
pulisher
Apr 25, 2026

TPST Stock Plummets After Inking Deal To Acquire CAR-T Programs From Privately-Held Firm In All-Stock Transaction - MSN

Apr 25, 2026
pulisher
Apr 24, 2026

Tempest Therapeutics stock falls after $4.25 million direct offering - MSN

Apr 24, 2026
pulisher
Apr 23, 2026

Tempest achieves manufacturing milestone for CAR-T therapy By Investing.com - Investing.com India

Apr 23, 2026
pulisher
Apr 22, 2026

Tempest Therapeutics provides update on development of TPST-2003 - TipRanks

Apr 22, 2026
pulisher
Apr 22, 2026

Tempest Therapeutics (TPST) Advances Dual-Targeting CAR-T Therap - GuruFocus

Apr 22, 2026
pulisher
Apr 22, 2026

Tempest achieves manufacturing milestone for CAR-T therapy - Investing.com

Apr 22, 2026
pulisher
Apr 22, 2026

Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T - GlobeNewswire

Apr 22, 2026
pulisher
Apr 20, 2026

Tempest Therapeutics (TPST) Stock: Why Spinoff Value (Tick Down) 2026-04-20Trending Buy Opportunities - Cổng thông tin điện tử tỉnh Lào Cai

Apr 20, 2026
pulisher
Apr 17, 2026

TPST Forecast, Price Target & Analyst Ratings | TEMPEST THERAPEUTICS INC (NASDAQ:TPST) - ChartMill

Apr 17, 2026
pulisher
Apr 15, 2026

Tempest Therapeutics names Andrew Fang head of business development By Investing.com - Investing.com India

Apr 15, 2026
pulisher
Apr 14, 2026

Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts - Bitget

Apr 14, 2026
pulisher
Apr 14, 2026

Tempest Therapeutics names Andrew Fang head of business development - Investing.com

Apr 14, 2026
pulisher
Apr 14, 2026

Tempest Appoints Andrew Fang, Ph.D., as Head of Business - GlobeNewswire

Apr 14, 2026
pulisher
Apr 13, 2026

Tempest Therapeutics(TPST) Stock Options Chain | Quotes & News - Moomoo

Apr 13, 2026
pulisher
Apr 12, 2026

Form S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments - ADVFN

Apr 12, 2026
pulisher
Apr 10, 2026

Tempest Therapeutics (NASDAQ: TPST) registers 2.78M resale shares from private placement - Stock Titan

Apr 10, 2026
pulisher
Apr 10, 2026

Tempest Therapeutics (NASDAQ: TPST) registers 8.27M shares for resale by sellers - Stock Titan

Apr 10, 2026
pulisher
Apr 10, 2026

Buyout Rumor: What is Stran Company Incs revenue forecast2026 Technical Patterns & Weekly Breakout Stock Alerts - baoquankhu1.vn

Apr 10, 2026
pulisher
Apr 10, 2026

New Strong Buy Stocks for April 10th - The Globe and Mail

Apr 10, 2026
pulisher
Apr 10, 2026

Can Tempest Therapeutics (TPST) Stock Maintain Growth | Price at $1.79, Up 13.29%Community Chart Signals - Cổng thông tin điện tử Tỉnh Sơn La

Apr 10, 2026
pulisher
Apr 10, 2026

[EFFECT] Tempest Therapeutics, Inc. SEC Filing - Stock Titan

Apr 10, 2026
pulisher
Apr 03, 2026

Tempest Therapeutics, Inc. announced that it has received $1.999539 million in funding from Factor Bioscience Inc. and other investors - marketscreener.com

Apr 03, 2026
pulisher
Apr 02, 2026

Tempest Therapeutics (TPST) grants 22,000 stock options to Corporate Controller - Stock Titan

Apr 02, 2026
pulisher
Apr 02, 2026

Tempest Therapeutics (TPST) CFO receives 140,000 stock options at $1.64 - Stock Titan

Apr 02, 2026
pulisher
Apr 02, 2026

Versant funds report lower Tempest Therapeutics (TPST) ownership levels - Stock Titan

Apr 02, 2026
pulisher
Apr 02, 2026

Biopharmaceutical company Tempest Therapeutics Inc (TPST) recently filed a prospectus with the U.S. Securities and Exchange Commission, planning to issue up to approximately 2.8 million common shares through resale, including related warrants. - Bitget

Apr 02, 2026
pulisher
Apr 02, 2026

According to a filing submitted to the US Securities and Exchange Commission (SEC), Tempest Therapeutics Inc. will not receive any proceeds from the sale of the company's shares by selling shareholders. - Bitget

Apr 02, 2026
pulisher
Apr 01, 2026

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Tempest Therapeutics (TPST) - The Globe and Mail

Apr 01, 2026
pulisher
Apr 01, 2026

Tempest Therapeutics | UPLOAD: Others - Moomoo

Apr 01, 2026
pulisher
Mar 31, 2026

H.C. Wainwright Maintains Tempest Therapeutics(TPST.US) With Buy Rating, Maintains Target Price $11 - moomoo.com

Mar 31, 2026
pulisher
Mar 31, 2026

TPST Q4'25 Earnings: EPS estimate is (0.62) USD - TradingView — Track All Markets

Mar 31, 2026
pulisher
Mar 30, 2026

According to the latest filing disclosed by the SEC, existing shareholders of biopharmaceutical company Tempest Therapeutics Inc. plan to resell up to 8.27 million shares of the company's common stock. - Bitget

Mar 30, 2026
pulisher
Mar 30, 2026

Scienture Holdings Inc (MEDS) Reports FY2025 Earnings - AlphaStreet

Mar 30, 2026
pulisher
Mar 30, 2026

Tempest Reports Year End 2025 Financial Results and Provides Business Update - bitget.com

Mar 30, 2026
pulisher
Mar 30, 2026

Tempest reports year end 2025 financial results and provides business update - marketscreener.com

Mar 30, 2026
pulisher
Mar 30, 2026

Tempest Therapeutics, Inc. (TPST) Reports FY2025 Earnings - AlphaStreet

Mar 30, 2026
pulisher
Mar 30, 2026

Tempest Therapeutics 2026 10-K: Pipeline Overview, CAR-T & Small Molecule Oncology Strategies, Key Partnerships, and Competitive Position - Minichart

Mar 30, 2026
pulisher
Mar 30, 2026

Tempest's new CEO arrives as six myeloma patients hit complete response - Stock Titan

Mar 30, 2026

Finanzdaten der Tempest Therapeutics Inc-Aktie (TPST)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$28.32
price down icon 0.14%
$50.44
price up icon 0.48%
$95.50
price down icon 3.88%
$139.44
price down icon 0.41%
$147.21
price down icon 0.47%
ONC ONC
$297.49
price up icon 0.12%
Kapitalisierung:     |  Volumen (24h):